ALNY vs ROIV
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ALNY · Alnylam Pharmaceuticals$155.94 ▼ 0.46%
ROIV · Roivant Sciences$38.88 ▲ 6.17%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ALNY -64.7%
- ROIV +83.7%
Head to head
| Metric | ALNY | ROIV |
|---|---|---|
| Price | $155.94 | $38.88 |
| Change today | ▼ 0.46% | ▲ 6.17% |
| Market cap | $20.89B | $28.08B |
| Return, 3 months | -28.1% | +8.7% |
| Return, year to date | -60.8% | +79.2% |
| Return, 1 year | -64.8% | +88.6% |
| P/E (TTM) | 8.1 | – |
| P/B | 5.8 | 6.6 |
| P/E percentile vs own 5y | 80th | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +66.9% | -33.5% |
| Net profit growth (YoY) | +327.7% | -6.1% |
| Gross margin | 79.7% | 81.2% |
| Operating margin | 20.8% | -18,146.1% |
| Net margin | 16.1% | -3,535.0% |
| Return on equity | 96.6% | -6.2% |
| Analyst target vs. price | +103.5% | +24.6% |
| Analyst buy share | 76% | 82% |
| RSI (14) | 22 | 60 |
| 30-day volatility | 90.9% | 43.7% |
| Max drawdown, 1 year | -67.6% | -20.2% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ROIV is the largest of the group by market value.
- ROIV has returned the most over the past year.
- ALNY is growing revenue fastest.
- ALNY keeps the most profit per dollar of sales.
- ROIV has been the calmest stock over the last 30 days.